US EditionPublished • loading... • Updated
TransThera Publishes Clinical Studies of Tinengotinib (TT-00420) against Cholangiocarcinoma on Lancet
- TransThera Sciences Inc. announced that clinical results from a Phase 2 trial of tinengotinib were published in The Lancet Gastroenterology and Hepatology.
- The trial involved patients with FGFR2 fusion-positive Cholangiocarcinoma who had resistance to prior FGFR inhibitor therapy.
- Tinengotinib showed clinical activity and durable responses in patients with FGFR2 fusion-positive Cholangiocarcinoma.
- This study offers insights into treatment strategies for patients with FGFR-altered Cholangiocarcinoma.
Insights by Ground AI
67 Articles
67 Articles
TransThera 在Lancet上发表 Tinengotinib (TT-00420) 治疗胆管癌的临床研究 – DIR HONGKONG
(SeaPRwire) – 中国南京和马里兰州盖瑟斯堡, 2025年12月4日 — TransThera Sciences Inc.（简称“TransThera”）宣布，关于评估tinengotinib治疗胆管癌（CCA）患者的美国2期临床试验结果已在《柳叶刀胃肠病学和肝病学》（The Lancet Gastroenterology and Hepatology）（影响因子：38.6）上发表。 胆管癌（CCA）是一种侵袭性胆管恶性肿瘤，常由FGFR2融合驱动，这是一种可通过FGFR抑制剂（如pemigatinib和futibatinib）靶向的基因组改变。然而，对这些药物的耐药性常因继发性FGFR2突变而产生。 在一项多中心、开放标签的2期临床试验（NCT04919642）中，招募了先前接受FGFR抑制剂（FGFRi）治疗后出现原发性耐药或获得性耐药的FGFR2融合阳性CCA患者，以及携带其他FGFR改变或FGFR野生型肿瘤的患者。Tinengotinib在FGFRi获得性耐药的F…
Coverage Details
Total News Sources67
Leaning Left6Leaning Right7Center23Last UpdatedBias Distribution64% Center
Bias Distribution
- 64% of the sources are Center
64% Center
L 17%
C 64%
R 19%
Factuality
To view factuality data please Upgrade to Premium
